Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pablo D Perez-Moreno"'
Autor:
Jinming Yu, Andrés Cardona, Andrea Ardizzoni, Delvys Rodriguez-Abreu, Sergio Azevedo, Belen Rubio-Viqueira, Jorge Alatorre-Alexander, Hans J M Smit, Konstantinos Syrigos, Kerstin Trunzer, Hina Patel, Jonathan Tolson, Pablo D Perez-Moreno
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Atezolizumab treatment improves survival, with manageable safety, in patients with previously treated advanced/metastatic non-small cell lung cancer. The global phase III/IV study TAIL (NCT03285763) was conducted to evaluate the safety and
Externí odkaz:
https://doaj.org/article/ff460346035746668e4d5b72630465b6
Autor:
Peter Schmid, Charles E. Geyer Jr, Nadia Harbeck, Mothaffar Rimawi, Sara Hurvitz, Miguel Martín, Sherene Loi, Shigehira Saji, Kyung Hae Jung, Gustavo Werutsky, Daniil L. Stroyakovsky, Vanesa López-Valverde, Michael Davis, Tanja Badovinac Crnjevic, Pablo D. Perez-Moreno, Aditya Bardia
Publikováno v:
Cancer Research. 83:OT2-03
BACKGROUND Endocrine therapies (ETs) that target estrogen receptor (ER) activity and/or estrogen synthesis are the mainstay of ER+ breast cancer (BC) treatment. Despite best management, ≤20% of patients (pts) with ER+/HER2– early BC (eBC) develop
Autor:
Elgene Lim, Marianna Chavez, Aditya Bardia, Joo Hyuk Sohn, Heather M. Moore, Mahesh Shivhare, Jorge Martinalbo, Laura Roncoroni, Pablo D. Perez-Moreno, Miguel Martín
Publikováno v:
Cancer Research. 83:PD13-04
BACKGROUND Endocrine therapy (ET) is the mainstay for management of estrogen receptor (ER)+ advanced breast cancer (aBC). Giredestrant is a highly potent, nonsteroidal, oral selective ER antagonist and degrader (SERD) that achieves robust ER occupanc
Autor:
Jorge Arturo Alatorre-Alexander, Hina Patel, Kerstin Trunzer, Delvys Rodriguez-Abreu, Jinming Yu, T. Newsom-Davis, Andrea Ardizzoni, Konstantinos N. Syrigos, A. Cardona, Pablo D Perez-Moreno, Jonathan Tolson, Sergio J. Azevedo, Hans J.M. Smit, Belen Rubio-Viqueira
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAtezolizumab treatment improves survival, with manageable safety, in patients with previously treated advanced/metastatic non-small cell lung cancer. The global phase III/IV study TAIL (NCT03285763) was conducted to evaluate the safety and